109 results
Page 4 of 6
6-K
EX-99.1
0bfjw0
1 Jul 20
Last of 12,400 Participants Completes Final Visit in BiondVax’s M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial
8:19am
6-K
EX-99.1
5ph8g q7tr
1 Jul 20
BiondVax Announces First Quarter 2020 Financial Results
6:14am
6-K
EX-99.1
gif 4rpqqcg
12 Jun 20
BiondVax Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
8:10am
6-K
EX-99.1
hvidhszv
10 Jun 20
NIH Report on Phase 2 Clinical Trial of BiondVax’s M-001 Universal Influenza Vaccine Candidate Concludes Both Primary Endpoints Achieved
7:47am
6-K
EX-99.1
o4gbjl29z 61rb8gp
20 May 20
BiondVax Announces Receipt of $4.2 million through Exercise of Warrants
7:43am
6-K
EX-99.1
kf6swg8wb qtxn
4 May 20
BiondVax Announces Upcoming Expiration of Public Warrants
10:48am
6-K
00y9npm9 le
30 Apr 20
Report of Foreign Private Issuer
9:39am
6-K
EX-99.1
d1hecjdqv5rogx6z
24 Mar 20
New Directors Elected to BiondVax’s Board of Directors
4:28pm
6-K
EX-99.1
0pr76swmbbu7aic m8r
19 Mar 20
BiondVax’s CEO Comments on Impact of COVID-19 Pandemic on the Company’s Ongoing Phase 3 Clinical Trial
1:05pm
6-K
ord3ug57
19 Mar 20
BiondVax’s CEO Comments on Impact of COVID-19 Pandemic on the Company’s Ongoing Phase 3 Clinical Trial
1:05pm
6-K
EX-99.1
2f80vfq
5 Feb 20
Current report (foreign)
3:24pm
6-K
EX-99.3
kwc5sa
16 Jan 20
Amendment No. 1 to Ads Warrant Agent Agreement
2:47pm
POS AM
ewrjrx3vs0b0ducf
7 Jan 20
Prospectus update (post-effective amendment)
10:51am
6-K
EX-99.1
dh6 ob1erme3
26 Nov 19
BiondVax Announces Third Quarter 2019 Financial Results and Business Update
2:19pm
6-K
EX-99.1
052fph81mhf
18 Nov 19
Enrollment and randomization of 12,463 participants complete in BiondVax’s pivotal, clinical efficacy, Phase 3 Universal Flu Vaccine trial
1:25pm
6-K
EX-99.1
jhrnj gvia7p
8 Oct 19
BiondVax receives €4M from the European Investment Bank (EIB) in support of ongoing Universal Influenza Vaccine Pivotal Phase 3 trial
6:01am
6-K
EX-99.1
89t mmnmpefoa
28 Aug 19
Second Quarter 2019 Financial Results
10:50am
6-K
EX-99.1
brdnzpz b7
16 Jul 19
BiondVax Announces Rights Offering Fully Subscribed at US$20 Million
10:25am
6-K
EX-99.1
jnh6ko2s 0kcjrl1k8
8 Jul 19
Current Report of Foreign Issuer
8:29am